Counseling Patients on Ruxolitinib: Expectations, Response, and the Extended-Release Shift

This segment focuses on how clinicians frame ruxolitinib for patients entering steroid-refractory chronic GVHD care. Drawing on the REACH3 experience, faculty describe how they translate the data into patient-facing expectations: a better chance of response than best available therapy, event-free survival without GVHD-related events, and meaningful, durable symptom relief that supports quality of life, role function, and a return to normalcy. Central to the conversation is steroid sparing, and the message that patients who achieve complete remission may eventually discontinue therapy, an outcome patients are eager to hear. The discussion then turns to the once-daily extended-release formulation and why it matters in a population burdened by polypharmacy. Faculty note comparable efficacy and safety to twice-daily dosing, with the practical benefit of one fewer pill each day improving adherence and tolerability. The segment underscores clear, honest counseling on both efficacy and safety as foundational to the treatment relationship.